E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic progressive castration-resistant prostate cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Progressive prostate cancer resistant to androgen suppression |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10062904 |
E.1.2 | Term | Hormone-refractory prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of radiographic progression-free survival (rPFS) |
|
E.2.2 | Secondary objectives of the trial |
Evaluation of overall survival (OS)
Evaluation of prostate-specific antigen (PSA) response
Evaluation of time to PSA progression
Evaluation of the safety of enzalutamide
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject has histologically confirmed adenocarcinoma of the prostate without neuro-endocrine differentiation or small cell features.
2. Subject has metastatic disease documented by bone scan or by soft tissue disease observed by CT/MRI at screening, or within ≤ 30 days prior to Day 1.
3. Subject has a serum testosterone of ≤ 1.7 nmol/L (or ≤ 50 ng/dL) at screening.
4. In the setting of castrate levels of testosterone ≤1.7 nmol/L (or ≤50 ng/dL), subject has progressive disease at study entry defined as PSA rise determined by a minimum of 2 rising PSA levels with an interval of ≥ 1 week between each assessment. The PSA value at the screening visit should be ≥ 2 ng/mL WITH or WITHOUT:
• Soft tissue disease progression defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.1) at screening or within ≤ 30 days prior to Day 1. Measurable disease is not required for entry. Lymph nodes ≥ 2 cm are considered measurable disease (PCWG2).
• Bone disease progression defined by at least 2 new lesions on bone scan at screening or within ≤ 30 days prior to Day 1.
5. Subject must have received a minimum of 24 weeks of treatment with abiraterone acetate and has discontinued use at least 4 weeks prior to start of study drug at Day 1.
6. If the subject has received previous treatment with chemotherapy for prostate cancer, this must be limited to no more than one prior line of docetaxel, and must have been used prior to abiraterone acetate therapy.
7. Subject receives and will continue to receive ongoing androgen deprivation with LHRH analogue therapy throughout the course of the study or has had a bilateral orchiectomy.
Subject is asymptomatic or mildly symptomatic from prostate cancer:
• The score on BPI-SF Question #3 must be < 4.
• No use of opiate analgesics for prostate cancer-related pain currently or anytime within 4 weeks prior to screening.
|
|
E.4 | Principal exclusion criteria |
1. Subject has prior use of ketoconazole for the treatment of prostate cancer.
2. Subject has prior use of cabazitaxel.
3. Subject has prior use of enzalutamide.
4. Subject has received ANY anti-neoplastic therapy (including antiandrogens and chemotherapy) following abiraterone acetate discontinuation and prior to start of study drug at Day 1.
5. Subject has a known or suspected hypersensitivity to enzalutamide, or any components of the formulation used.
6. Subject has known or suspected brain metastases or active leptomeningeal disease.
7. Subject has history of seizure or any condition that may predispose to seizure (e.g., prior stroke or significant brain trauma).
8. Subject has history of loss of consciousness or transient ischemic attack within 12 months of screening.
9. Subject has concurrent disease or any clinically significant abnormality following the investigator’s review of the physical examination, electrocardiogram (ECG) and safety laboratory tests at screening, which in the judgment of the investigator would interfere with the subject's participation in this study or evaluation of study results.
10. Subject has a history of another invasive cancer within 3 years prior to screening, with the exception of non-melanoma skin cancers that have a remote probability of recurrence in the opinion of the Investigator in consultation with the medical monitor.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Radiographic progression-free survival (rPFS) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Time from first dose to the first objective evidence of radiographic disease progression or death from any cause, whichever occurs first. For subjects who are alive and free of radiographic progression at the time of the analysis data cut-off point, rPFS time will be censored on the date of the last radiographic assessment showing no evidence of progression prior to the analysis data
cut-off point. |
|
E.5.2 | Secondary end point(s) |
Overall survival (OS)
PSA response defined as the proportion of subjects with at least 50% decrease from baseline in PSA
Time to PSA progression (TPP) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
OS: Time from first dose to death from any cause. For subjects who are alive at the time of the analysis data cut-off point, OS time will be censored on the last date the subject is known to be alive.
PSA response: Timepoint when lowest PSA valuel is observed post-baseline.
TPP: Timepoint when ≥ 25% increase and an absolute increase of ≥ 2 µg/L are observed. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |